**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 5978**

**Columns:** **TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (6): *Helicobacter pylori*

***Helicobacter pylori*: Future perspectives in therapy reflecting three decades of experience**

Kanizaj TF *et al*. *H. pylori*: Future perspectives in therapy

Tajana Filipec Kanizaj, Nino Kunac

**Tajana Filipec Kanizaj,** Department of gastroenterology, University hospital Merkur, School of Medicine, University of Zagreb, Zagreb 10000, Croatia

**Nino Kunac,** University hospital Merkur, Zagreb 10000, Croatia

**Author contributions:** Kanizaj TF and Kunac N contributed equally to this work and wrote the paper; Kanizaj TF designed the theme topic; Kanizaj TF and Kunac N equally performed the research, analysis and interpretation of published data; Kunac N searched the relevant literature.

**Correspondence to: Tajana Filipec Kanizaj, PhD, Assistant Professor,** Department of gastroenterology, University hospital Merkur, School of Medicine, University of Zagreb, Zajceva 19, Zagreb 10000, Croatia. tajana\_filipec@yahoo.com

**Telephone:** +385-98623903 **Fax:** +385-12431393

**Received:** September 28, 2013  **Revised:** December 5, 2013

**Accepted:** January 2, 2014

**Published online:**

**Abstract**

The rising prevalence of antibiotic resistance has created a need to reassess the established *Helicobacter pylori* (*H. pylori*) eradication protocols, and to develop new ones. Various bacterial and host factors are evaluated, and their contribution to eradication failure is estimated. For a long time being considered the cornerstone eradication scheme, the standard triple therapy has been replaced with novel, more efficient regimens, namely sequential and concomitant, along with the emergence of a new design of bismuth quadruple therapy. A rescue levofloxacin based regimen has overcome the fear of therapy failure due to higher prevalence of dual resistant (clarithromycin and metronidazole) *H. pylori*. Culture-free and efficient susceptibility test are reestablishing the concept of tailored therapy, making eradication success close to originally desirable rates. Alleviating therapy side effects and improving patient compliance are as important as choosing appropriate eradication schemes, so various probiotic compound supplements are taken into consideration. Finally, we summarize the emerging efforts and obstacles in creating efficient *H. pylori* vaccine.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** *Helicobacter pylori*; Eradication therapy; Antibiotic resistance; First line therapy; Rescue therapy; Sequential therapy; Bismuth-containing quadruple therapy; Concomitant quadruple therapy; Hybrid (dual-concomitant) therapy

**Core tip:** In this article the authors have made a review of the most important literature with knowledge of various factors affecting *Helicobacter pylori* eradication success. The paper presents an analysis of established and new eradication regimens, as well as factors affecting their performance. Since the last 3 decades many new developments appeared in the field of this intriguing infection, along with implementation of recently published guidelines. Authors made a new look to future perspectives in managing this complex infection.

Kanizaj TF, Kunac N. *Helicobacter pylori*: Future perspectives in therapy reflecting three decades of experience.

**Available from:** URL: http://www.wjgnet.com/1007-9327/

**DOI:** http://dx.doi.org/10.3748/

**INTRODUCTION**

*Helicobacter pylori* (*H. pylori*) is a gram-negative, microaerophilic bacterium inhabiting human stomach, first isolated by Warren and Marshall in 1983, and that has since then become a point of interest worldwide[1]. It is a major pathogen causing gastric and duodenal ulcer, gastric cancer and mucosa-associated lymphoid tissue lymphoma[2,3]. Recently, it has been linked to extragastric malignancies such as colorectal adenocarcinoma and nonmalignant diseases such as iron deficiency anemia, idiopathic thrombocytopenic purpura and vitamin B12 deficiency, with new data on its role in neurodegenerative diseases and metabolic syndrome[2,4,5].

During three decades of *H. pylori* eradication, various therapeutic protocols have emerged, with the standard triple therapy recently succeeding generally bellow 80%, far away from the originally expected rate of > 90%[6-9].Possible factors causing progressive eradication therapy failure have been evaluated, with the consensus that antibiotic resistance and patient compliance are the most important ones[6-9].Accordingly, common opinion is that local antibiotic resistance screening and detailed evaluation of patient prior antibiotic usage, are main steps in preventing further eradication rate decline[2,7,9,10-12].

In this article we will review the most important results of various established and novel eradication protocols and the factors affecting them, along with a look to new perspectives in managing this complex and intriguing infection.

**BACTERIA AND HOST INFLUENCING ERADICATION**

There are multiple factors, concerning both the bacteria and the host, making *H. pylori* eradication so difficult. Factors affecting proton pump inhibitor metabolism and bioavailability, such as CYP2C19 and MDR1 polymorphism, and the IL-1B polymorphism affecting intragastric acidity, were implied in eradication success rate, with fast metabolizers and acid hypersecretors found to have lower therapy success[6,13,14]. Several studies have shown lower eradication rates in patients with non-ulcer dyspepsia compared to peptic ulcer disease. The reason may be that patients with non-ulcer dyspepsia seem to be infected with less virulent, slow-proliferating strains, making them less susceptible toward antibiotics, with those strains more frequently being resistant to clarithromycin[13,14].More contradictory data were published about negative impact of increased body mass, diabetes and smoking on eradication rate[13,15]. Finally, before evaluating any cause of eradication failure, physicians must be aware of patient compliance, as those taking < 80% of their treatment regimen have a high chance of failure and subsequent antimicrobial resistance[12,14].

Multiple bacterial factors are influencing eradication therapy success rate, with the development of resistance to antibiotics as the most important[9,10,16]. Recent multicenter study by Megraud *et al*[16] showed that resistance rates in Europe for adults were 17.5% for clarithromycin, 14.1% for levofloxacin and 34.9% for metronidazole, with rates higher in Western/Central and Southern Europe than in Northern Europe. A steady increase in clarithromycin resistance and almost doubling of levofloxacin resistance was noted, linked with an increase in outpatient antibiotic usage[7,16,17]. As opposed to emerging resistance to previously mentioned antibiotics, resistance to amoxicillin, bismuth, furazolidone and tetracycline remains low[9]. The implication of antibiotic resistance is mainly accentuated with clarithromycin. In the case of clarithromycin resistance the rate of success of clarithromycin-containing regimen is very low (10%-30%). Metronidazole resistance is associated with 5%-25% lower eradication rate[10,18]. Levofloxacin, as metronidazole resistance can be overcome with increasing the length of treatment and using bismuth in quadruple therapy[16,19]. Other contributing factors are the presence of dormant coccoid bacterial forms, the density of *H. pylori* in the stomach, virulence factor status, biofilm formation, intracellular location of the bacteria and the presence of multistrain infection[13-15,20,21]. The presence of dormant, non-replicating bacteria causes phenotypic resistance, which is a form of reversible antibiotic resistance causing treatment failure[9].

**FIRST LINE ESTABLISHED AND NOVEL TREATMENT OPTIONS**

Standard triple therapy (proton pump inhibitor-PPI, clarithromycin, amoxicillin or metronidazole for 7-14 d) was a cornerstone of *H. pylori* treatment for years, recently gaining unacceptable eradication rates, mainly due to increase in clarithromycin resistance. According to new Maastricht guidelines, it is not advisable to use standard triple therapy in areas with clarithromycin resistance over 15%-20%, what lead to revival of some forgotten regimens, and construction and evolution of new ones[6,8]. Considering the fact that it is possible to overcome the resistance to metronidazole and that resistance to certain antibiotics rarely develops, new eradication schemes of various duration and dosage with strong inhibition of acid secretion, have been constructed to bypass triple therapy failure[16].

Bismuth-containing quadruple therapy represents alternative tostandardtriple therapyin areaswith low clarithromycin resistance and the main first-line therapeutic option for areas with high prevalence of clarithromycin resistance. Consisting of bismuth salt, tetracycline and metronidazole it is effective independently of clarithromycin resistance. By using this regimen at full doses and for 14 d one can expect 95% or greater treatment success, irrespective of the level of metronidazole resistance[22]. Therapy for 7, and likely 10 d is very susceptible to metronidazole resistance, however, the prevalence of resistance, which results in a decrease in outcome to less than 90%, is probably approximately 30%[18]. Unfortunately recent meta-analysis, evaluating empirical approach with bismuth-containing quadruple or standard triple eradication regimen, revealed suboptimal data (78.3% and 77% eradication therapy success)[23]. Possible negative effects of metronidazole resistance could be resolved with increased dosage and longer duration of treatment (10-14 d). This regimen has been sometimes marginalized through literature considering the unavailability of bismuth salts and tetracycline worldwide, complex dosing scheme, not yet known optimal dose and adverse effects[6]. After a study by Malfertheiner *et al*[24,25] in 2011, a revival of a quadruple regime consisting of PPI with a 3 in 1 capsule containing bismuth subcitrate potassium, metronidazole and tetracycline has emerged with improved eradication success exceeding 90%.

The PPI component of *H. pylori* eradication regimens has a major influence on overall therapy success, due to its intrinsic antibacterial effect, and more importantly the possibility to convert the nonproliferating, dormant forms of bacteria into active, proliferating forms by raising pH, leading to higher antibiotic efficacy[26]. Recent studies with new generation PPIs (esomeprazole and rabeprazole) have shown their higher potency in raising pH irrespective of CYP2C19 polymorphism, with eradication rate improvement[27,28].

First developed in Italy in the 90s, sequential therapy (5 d PPI and amoxicillin, followed by 5 d PPI, clarithromycin and metronidazole), is a regime that was proven to be more efficacious than triple therapy in many studies[8,29-32]. Recent multicenter randomized trial in Taiwan showed superiority of sequential over standard triple therapy, adding to its confirmation on population outside Italy[33]. The ability to eradicate the clarithromycin resistant bacteria has been demonstrated, and a sequential therapy has been already included in the recent consensus report as a valid first line option in geographic regions with high clarithromycin resistance[6]. Possible limitation of this regimen could be related to inferior results in treatment of dual resistant strains[30]. The level of metronidazole resistance determines the level of clarithromycin resistance required for eradication regimen success to decrease to < 90%. In low clarithromycin resistance areas metronidazole resistance undermines 10 d sequential therapy when it reaches 20%, and 14 d sequential therapy at approximately 30%. If metronidazole resistance is absent or low, sequential therapy for 10 or 14 d is very mildly affected with clarithromycin resistance. The complexity of sequential therapy was frequently reported as a possible problem of that regimen. Since this issue was never objectively evaluated, comparative studies of different therapy regimens (by using questionnaire, by prescriptive time evaluation *etc.*) are needed. The mechanism behind sequential therapy success is thought to be the disruption of the bacterial wall with initial 5 d of amoxicillin therapy, what prevents formation of efflux channels and consequent resistance for clarithromycin[15,34]. Nevertheless, a lot of authors have been hypothesizing that the use of 3 antibiotics, rather than the sequential scheme of administration, adds to this regime efficacy[15,35,36]. In this situation, adding to complexity and possible lower adherence to therapy, complexity of sequential administration would be unnecessary.

Two novel eradication regimens, namely concomitant (PPI, clarithromycin, amoxicillin, metronidazole for 10 d) and hybrid (PPI and amoxicillin for 7 d, followed by PPI, amoxicillin, clarithromycin and metronidazole for 7 d), have proven their efficacy over triple and sequential therapy in the last few years, especially with dual (clarithromycin and metronidazole) resistant strains[15,37-43]. Several studies have demonstrated that concomitant therapy is more effective (with comparable side effects) than standard triple therapy, although highly variable efficacy is reported with concomitant therapy and optimal treatment duration is not defined[36,44]. Most of these studies were performed with shorter (5-7 d) schemes. Meta-analyses and recent head-to-head comparison in Thailand have shown that the outcome of concomitant therapy is duration dependent[44-46]. Unsatisfactory results have been recently reported even when this scheme was adopted for two weeks. One of the findings ofa large randomized trial in Latin America showed that 14 d triple therapy is more effective than 5 d concomitant or 10 d sequential therapy[47]. Geographic variations in the pattern of *H. pylori* resistance to antibiotics might account for some of these discrepancies in results, accentuating the need for implementation of local resistance pattern knowledge in generalized eradication therapy recommendations. Some of the advantages of non-bismuth quadruple regimens over the sequential regimen are longer duration of all the prescribed antibiotics, and broader validation in randomized controlled trials (RCT) of wider geographical regions[39]. A recent RCT in Spain over 338 patients, showed a slight advantage of concomitant over sequential therapy, allowing close to 90% eradication rates[34]. Non-bismuth eradication schemes are recommended as first line therapy in areas with high clarithromycin resistance (> 15%-20%) where bismuth containing quadruple therapy is not locally available[6]. The problem with empirical application of concomitant regimen is dual metronidazole–clarithromycin resistance. Before final conclusions on topic of concurrent versus sequential regimen further wider geographical region studies are essential in populations with high dual resistance.

A recently proposed hybrid therapy has been proven equally effective to 14 d concomitant regimen in a pilot study (ITT eradication rate 90% *vs* 92%)[37]. Therefore it could be considered in the same populations where concomitant therapy is recommended. This is a novel regimen, with only few evaluation studies published, so the optimal therapy duration and success rates in populations with high dual resistance are still not defined. This protocol is more complicated than those earlier proposed, with retained complex sequential approach and possible higher side effects rates because of concomitant treatment in the second phase. According to the preliminary data it is associated with comparable side effect profile and therefore merits consideration in further comparative studies in order to define final conclusions[10].

When considering an eradication protocol in first, and especially multiple therapy line failure, it is of utmost importance to reassess patients compliance and prior antibiotic usage, to design a scheme according to local resistance patterns and therapy success, and always confirm successful eradication[6,7,9,10,15]. Because of emergence of resistance to previously used antibiotic, it is advisable not to use the same antibiotic after therapy failure, and to modify the scheme duration, dosage and antisecretory effect, with addition of antibiotics for which resistance rarely develops[48,49]. After second line treatment failure it is recommended to perform culture and susceptibility testing prior to third line treatment[6]. An expert agreement is thatculture susceptibility testing before first or second line therapy is not advisable. With known obstacles of culture susceptibility testing, such as the need for endoscopic examination, the fact that culture is time-consuming, costly and not 100% sensitive and that susceptibility knowledge is not always followed with accordant eradication, highly effective empiric first line and rescue regimens can achieve acceptable results[8,15,50].

**RESCUE REGIMENS**

Several rescue regimens have been evaluated in recent years, especially with worldwide rise of clarithromycin and metronidazole resistance. Bismuth quadruple regimes are recommended as first and second line treatment options in areas of high clarithromycin resistance[6]. Based on analysis of 30 studies, after first line standard triple regimen, mean second line bismuth quadruple regimes yielded 77% eradication therapy success. Major determinants of eradication efficacy were metronidazole dosage and treatment duration[49].

Another rescue regimen recommended by the Maastricht guidelines for second and third line therapy, is the triple levofloxacin protocol (PPI, levofloxacin and amoxicillin for 10-14 d)[6]. It is especially valuable in situations where sequential and concomitant regimens where used, and where highly possibly dual resistant bacteria emerged[49,51]. Recently Gisbert *et al*[52] evaluated levofloxacin rescue therapy after sequential and concomitant treatment, and presented an encouraging eradication rate of 75%[52]. When comparing levofloxacin triple therapy to bismuth quadruple therapy, which fails in around 20%-30% of patients, several meta-analyses have shown better outcomes with the levofloxacin regimen[48,53]. Besides being established as a rescue protocol, levofloxacin based therapy has proven its efficacy as a first line treatment, although not generally recommended due to rapid emergence of fluoroquinolone resistance and adverse effects[8,15,53]. In contrast to metronidazole there is no dose dependent-effect in overcoming levofloxacin resistance (eradication protocols becomes ineffective when resistance reaches 13%). In a randomized controlled study by Federico *et al*[35], a 5 d levofloxacin concomitant and 10 d sequential scheme in treatment naïve patients, achieved per-protocol eradication rates of 96.5% and 95.5%, respectively.An interesting study from Australia, evaluating fluoroquinolone containing regimens, showed high eradication rates around 95% with quadruple therapy consisting of PPI, amoxicillin or bismuth subcitrate, rifabutin and ciprofloxacin, in patients who failed at least one therapy course[54]. Considering overall resistance issues, possibly better fluoroquinolone-containing regimens include fluoroquinolone-bismuth therapy and fluoroquinolone concomitant therapy. Since neither of this protocol has been optimized or tested widely, generally they should be used as tailored therapies especially in the context of the emerging levofloxacin resistance[10].

Aside from tailored therapy according to culture susceptibility testing, few antibiotics with practically inexistent resistance have been evaluated. Rifabutin, a rifamycin derivate commonly used to treat *Mycobacterium avium*-*intracellulare*, has shown promising eradication rates in patients with several therapy failures. The eradication rates for second-, third- and forth and more line therapies are 79%, 66% and 70% respectively[55]. It is marginalized in *H. pylori* treatment due to its high cost, severe side effects, primarily myelotoxicity, and possibility of multiresistant *Mycobacterium tuberculosis* emergence[56]. Additional studies are needed to optimize the regimen in terms of dose and duration. Due to low primary bacterial resistance, furazolidone was evaluated as a multiple failure rescue regimen, but has not found an established position, mainly due to its possible genotoxic and carcinogenic effect[57].

**WHAT THE FUTURE BRINGS?**

As evident from myriad emerging studies evaluating established and creating new *H. pylori* eradication schemes recently, a consensus therapy has not yet been achieved. Main factors for eradication therapy failure are antibiotic resistance and poor patient compliance[10]. With regard to before mentioned culture susceptibility testing deficiencies and highly effective first and second line empirical treatments, the so-called “tailored” eradication therapy has not yet taken effect. With the development of non-invasive, rapid and culture-free susceptibility tests, primarily for clarithromycin and levofloxacin, it would be easier to perform tailored therapy even for treatment of naïve patients, with achievement of originally expected eradication rate of > 95%[9,17]. The use of polymerase chain reaction, a fast and inexpensive, culture-free method for susceptibility testing, was proven to improve the eradication rate when used to create tailored therapy[58]. Recently a study from Taiwan was published, evaluating genotypic resistance-guided third-line sequential therapy and showing promising eradication results. Genotypic resistance testing is more convenient and rapid than standard culture susceptibility testing, with a possibility to determine resistance even from stool samples[59]. With more efficient susceptibility testing, local resistance surveillance would be easier to perform, adding to higher success of eradication therapy in general[7,9]. While waiting for generally available and reliable noninvasive susceptibility tests, allowing unrestricted application of tailored therapy, we should keep in mind that success rate of proposed regimens justify in many instances empirical application of first- and second- line therapies. Even with possibility that sometimes local or regional expert treatment guidelines will not be strictly in line with general ones, optimal approach is to use regimens that have been proven to be reliably excellent locally and/or regionally. Expert decisions should be based on knowledge of regional resistance patterns (obtained from imperative regional antimicrobial surveillance programs), local clinical experience with regard to which regimens are best effective and available and history of prior patient drug exposure. The regimen of the highest predicted success rate should apply with confirmation of successful eradication outcome. This approach allows us screening for possible increase in appearance of antimicrobial resistance in everyday clinical practice.

Besides the importance of knowing detailed patient antibiotic usage history and the ability of the physician to persuade the patient to take the medicines according to plan, a lot of effort is being made to reduce eradication therapy side effects. Various probiotic compounds containing *Lactobacillus*, *Bifidobacterium*, *Saccharomyce*s and other benevolent bacteria, have been evaluated in improving eradication rate and reducing therapy side effects. Their contribution to eradication therapy is accomplished through direct antibacterial effect, modulation of host immune response and stabilization of the mucosal barrier[60,61]. Few recent studies have shown beneficial effect of probiotic compounds on eradication rate and on diminishing therapy side effects, although results from different studies are contradictory, suggesting a need for further evaluation[61-63].

Development of a vaccine against *H. pylori* infection is an ultimate goal for eradicating all the negative effects of this versatile bacterium. There are several reasons for the fact that an efficient vaccine has not yet been developed. It took many years for the scientific community to acknowledge the contribution of *H. pylori* in peptic ulcer disease, and especially its carcinogenic potential. Another important factor is the complicated host immune response, along with considerable genetic diversity of *H. pylori*, what hampers the technical path in developing the vaccine. At last, due to a long period between *H. pylori* acquisition and manifestation of disease, especially gastric cancer, there is a general climate making development of the vaccine slow and inefficient[64,65].

**CONCLUSION**

A simple and uncomplicated path in *H. pylori* eradication has been recently disturbed with progressive bacterial resistance for cornerstone antibiotics. With the development and implementation of novel eradication regimens the situation looks more promising, although the final answer to *H. pylori* infection has not yet been established. Hopefully, non-invasive and rapid susceptibility tests will take place in strengthening the tailored therapy concept, and efficient vaccine will obviate the need for *H. pylori* induced disease management.

**REFERENCES**

1. **Warren JR**, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1983; **1**: 1273-1275 [PMID: 6134060]
2. **Malfertheiner P**, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. *Curr Opin Gastroenterol* 2012; **28**: 608-614 [PMID: 23010682 DOI: 10.1097/MOG.0b013e32835918a7]
3. **Shmuely H**, Katicic M, Filipec Kanizaj T, Niv Y. Helicobacter pylori and nonmalignant diseases. *Helicobacter* 2012; **17**: 22-25 [PMID: 22958151 DOI: 10.1111/j.1523-5378.2012.00978.x]
4. **Banic** M, Franceschi F, Babic Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. *Helicobacter* 2012; **17**: 49-55 [PMID: 22958156 DOI: 10.1111/j.1523-5378.2012.00983.x]
5. **Selgrad M**, Bornschein J, Rokkas T, Malfertheiner P. Helicobacter pylori: gastric cancer and extragastric intestinal malignancies. *Helicobacter* 2012; **17**: 30-35 [PMID: 22958153 DOI: 10.1111/j.1523-5378.2012.00980.x]
6. **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
7. **Graham DY**, Shiotani A. Which Therapy for Helicobacter pylori Infection? *Gastroenterology* 2012; **143**: 10-12 [PMID: 22613622 DOI: 10.1053/j.gastro.2012.05.012]
8. **Chuah SK,** Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy*. World J Gastroenterol* 2011; **17**: 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971]
9. **Graham DY**, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. *Gut* 2010; **59**: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]
10. **Graham DY**, Lee YC, Wu MS. Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence. *Clin Gastroenterol Hepatol* 2013 [Epub ahead of print] [PMID: 23751282 DOI: 0.1016/j.cgh.2013.05.028]
11. **Morgan DR**, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. *JAMA* 2013; **309**: 578-586 [PMID: 23403682 DOI: 10.1001/jama.2013.311]
12. **Vakil N**, Vaira D. Treatment for H. pylori infection: new challenges with antimicrobial resistance. *J Clin Gastroenterol* 2013; **47**: 383-388 [PMID: 23388847 DOI: 10.1097/MCG.0b013e318277577b]
13. **Zullo A**, De Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks! *J Clin Gastroenterol* 2012; **46**: 259-261 [PMID: 22395061 DOI: 10.1097/MCG.0b013e318247177e]
14. **De Francesco V**, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. *World J Gastrointest Pharmacol Ther* 2012; **3**: 68-73 [PMID: 22966485 DOI: 10.4292/wjgpt.v3.i4.68]
15. **Georgopoulos SD**, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. *Expert Opin Pharmacother* 2013; **14**: 211-223 [PMID: 23331077 DOI: 10.1517/14656566.2013.763926]
16. **Megraud F**, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* 2013; **62**: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]
17. **Giorgio F**, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A, Ierardi E. Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? *World J Gastrointest Pathophysiol* 2013; **4**: 43-46 [PMID: 23946886 DOI: 10.4291/wjgp.v4.i3.43]
18. **Fischbach L**, Evans EL. Meta analysis: the effect of antibiotic resistance status on the efficacy of triple and quandraple first-line therapies for Helicobacter pylori. *Aliment Pharmacol Ther* 2007; **26**: 343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]
19. **Couturier MR**, Marshall BJ, Goodman KJ, Mégraud F. Helicobacter pylori diagnostics and treatment: Could a lack of universal consensus be the best consensus? *Clin Chem* 2013 [Epub ahead of print] [PMID: 23908455 DOI: 10.1373/clinchem.2012.201475]
20. **Onal IK**, Gokcan H, Benzer E, Bilir G, Oztas E. What is the impact of Helicobacter pylori density on the success of eradication therapy: A clinic-histopathological study. *Clin Res Hepatol Gastroenterol* 2013; **37**: 642-646 [PMID: 23796974 DOI: 10.1016/j.clinre.2013.05.005]
21. **Cammarota G**, Sanguinetti M, Gallo A, Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. *Aliment Pharmacol Ther* 2012; **36**: 222-230 [PMID: 22650647 DOI: 10.1111/j.1365-2036.**2012**.05165.x ]
22. **Liang X**, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a pro- spective study. *Clin Gastroenterol Hepatol* 2013; **11**: 802–807 [PMID: 23376004 DOI: 10.1016/j.cgh.2013.01.008]
23. **Fischbach LA**, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. *Aliment Pharmacol Ther* 2004; **20**: 1071-1082 [PMID: 15569109 DOI: 10.1111/j.1365-2036.2004.02248.x]
24. **Malfertheiner P**, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011; **377**: 905-913 [PMID: 21345487 DOI: 10.1016/S0140-6736(11)60020-2]
25. **Venerito M**, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. *Digestion* 2013; **88**: 33-45 [PMID: 23880479 DOI: 10.1159/000350719]
26. **Marcus EA**, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. *Aliment Pharmacol Ther* 2012; **36**: 972-979 [PMID: 23009227 DOI: 10.1111/apt.12059]
27. **McNicholl AG**, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. *Aliment Pharmacol Ther* 2012; **36**: 414-425 [PMID: 22803691 DOI: 10.1111/j.1365-2036.**2012**.05211.x]
28. **Sánchez-Delgado J**, García-Iglesias P, Castro-Fernández M, Bory F, Barenys M, Bujanda L, Lisozain J, Calvo MM, Torra S, Gisbert JP, Calvet X. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. *Aliment Pharmacol Ther* 2012; **36**: 190-196 [PMID: 22591220 DOI: 10.1111/j.1365-2036.2012.05137.x]
29. **Rinaldi V**, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 1997; **11**: 929-933 [PMID: 9354202 DOI: 10.1046/j.1365-2036.1997.00228.x]
30. **Gisbert JP**, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. *J Clin Gastroenterol* 2010; **44**: 313-325 [PMID: 20054285 DOI: 10.1097/MCG.0b013e3181c8a1a3]
31. **Gatta L**, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. *BMJ* 2013; **347**: 4587-4601 [PMID: 23926315 DOI: 0.1136/bmj.f4587]
32. **Kate V**, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. *Drugs* 2013; **73**: 815-824 [PMID: 23625272 DOI: 10.1007/s40265-013-0053-z]
33. **Liou JM**, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. *Lancet* 2013; **381**: 205-213 [PMID: 23158886 DOI: 10.1016/S0140-6736(12)61579-7]
34. **McNicholl AG**, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP; On behalf of the participant centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. *Gut* 2013 [Epub ahead of print] [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820]
35. **Federico A**, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA, Rocco A, Ricciardiello L, Marmo R, Loguercio C, Romano M. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. *Gastroenterology* 2012; **143**: 55-61 [PMID: 22484118 DOI: 10.1053/j.gastro.2012.03.043]
36. **Gisbert JP**, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. *Clin Exp Gastroenterol* 2012; **5**: 23-34 [PMID: 22457599 DOI: 10.2147/CEG.S25419]
37. **Hsu PI**, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. *Helicobacter* 2011; **16**: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]
38. **Sardarian H**, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. *Helicobacter* 2013; **18**: 129-134 [PMID: 23121338 DOI: 10.1111/hel.12017]
39. **Molina-Infante J**, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. *Helicobacter* 2012; **17**: 269-276 [PMID: 22759326 DOI: 10.1111/j.1523-5378.2012.00947.x]
40. **Georgopoulos SD**, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical Evaluation of a Ten-Day Regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the Eradication of Helicobacter pylori in a High Clarithromycin Resistance Area. *Helicobacter* 2013; **18**: 459-467 [PMID: 23714140 DOI: 10.1111/hel.12062]
41. **Georgopoulos S**, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. *J Clin Gastroenterol* 2013; **47**: 228-232 [PMID: 22858517 DOI: 10.1097/MCG.0b013e31826015b0]
42. **Molina-Infante J**, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. *Gastroenterology* 2013; **145**: 121-128 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]
43. **Wu DC**, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. *Clin Gastroenterol Hepatol* 2010; **8**: 36-41 [PMID: 19804842 DOI: 10.1016/j.cgh.2009.09.030]
44. **Essa AS**, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. *Helicobacter* 2009; **14**: 109-118 [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671.x]
45. **Gisbert JP**, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. *Aliment Pharmacol Ther* 2011; **34**: 604-617 [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x]
46. **Kongchayanun C**, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. *Helicobacter* 2012; **17**: 282-285 [PMID: 22759328 DOI: 10.1111/j.1523-5378.2012.00953.x]
47. **Greenberg ER**, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. *Lancet* 2011; **378**: 507-514 [PMID: 21777974 DOI: 10.1016/S0140-6736(11)60825-8]
48. **Gisbert JP**. Rescue Therapy for Helicobacter pylori Infection 2012. *Gastroenterol Res Pract* 2012; **2012**: 974594 [PMID: 22536225 DOI: 10.1155/2012/974594]
49. **Marin AC**, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). *Expert Opin Pharmacother* 2013; **14**: 843-861 [PMID: 23537368 DOI: 10.1517/14656566.2013.782286]
50. **Gisbert JP**. Is culture necessary before first-line treatment for Helicobacter pylori infection? *Intern Med* 2011; **50**: 2719-2720 [PMID: 22041399 DOI: 10.2169/internalmedicine.50.5135]
51. **Gisbert JP**, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M, Rodrigo L, Ortuño J, Sánchez-Pobre P, Khorrami S, Franco A, Tomas A, Guerra I, Lamas E, Ponce J, Calvet X; H. pylori Study Group of the Asociación Española de Gastroenterología (Spanish Gastroenterology Association). Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. *J Clin Gastroenterol* 2013; **47:** 130-135 [PMID: 22647827 DOI: 10.1097/MCG.0b013e318254ebdd]
52. **Gisbert JP**, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. *Scand J Gastroenterol* 2013; **48**: 652-656 [PMID: 23556551 DOI: 10.3109/00365521.2013.786132]
53. **Cuadrado-Lavín A**, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A, González-Colominas E, Aresti-Zárate S, Hernández M, Pascual EL. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. *J Antimicrob Chemother* 2012; **67**: 2254-2259 [PMID: 22687889 DOI: 10.1093/jac/dks209]
54. **Tay CY,** Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. *Aliment Pharmacol Ther* 2012; **36**: 1076-1083 [PMID: 23072648 DOI: 10.1111/apt.12089]
55. **Gisbert JP**, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. *Aliment Pharmacol Ther* 2012; **35**: 941-947 [PMID: 22372560 DOI: 10.1111/j.1365-2036.**2012**.05053.x]
56. **Gisbert JP**, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. *Aliment Pharmacol Ther* 2012; **35**: 209-221 [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x]
57. **Zullo A**, Ierardi E, Hassan C, De Francesco V. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. *Saudi J Gastroenterol* 2012; **18**: 11-17 [PMID: 22249086 DOI: 10.4103/1319-3767.91729]
58. **Lee HJ**, Kim JI, Cheung DY, Kim TH, Jun EJ, Oh JH, Chung WC, Kim BW, Kim SS, Park SH, Kim JK. Eradication of Helicobacter pylori According to 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance. *J Infect Dis* 2013; **208**: 1123-1130 [PMID: 23801607 DOI: 10.1093/infdis/jit287]
59. **Liou JM,** Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, Tseng PH, Chang L, Chang WH, Wang HP, Shun CT, Wu JY, Lee YC, Lin JT, Wu MS; Taiwan Helicobacter Consortium. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. *J Antimicrob Chemother* 2013; **68**: 450-456 [PMID: 23099849 DOI: 10.1093/jac/dks407]
60. **Medeiros JA**, Pereira MI. The use of probiotics in Helicobacter pylori eradication therapy. *J Clin Gastroenterol* 2013; **47**: 1-5 [PMID: 23222208 DOI: 10.1097/MCG.0b013e3182702dbc]
61. **Shavakhi A**, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M, Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. *Helicobacter* 2013; **18**: 280-284 [PMID: 23433200 DOI: 10.1111/hel.12047]
62. **Du YQ**, Su T, Fan JG, Lu YX, Zheng P, Li XH, Guo CY, Xu P, Gong YF, Li ZS. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. *World J Gastroenterol* 2012; **18**: 6302-6307 [PMID: 23180952 DOI: 10.3748/wjg.v18.i43.6302]
63. **Navarro-Rodriguez T**, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, Bogsan CS, Chinzon D, Eisig JN. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. *BMC Gastroenterol* 2013; **13**: 56 [PMID: 23530767 DOI: 10.1186/1471-230X-13-5]
64. **Zhang S**, Moise L, Moss SF. H. pylori vaccines: why we still don't have any. *Hum Vaccin* 2011; **7**: 1153-1157 [PMID: 22048119 DOI: 10.4161/hv.7.11.17655]
65. **Ihan A**, Pinchuk IV, Beswick EJ. Inflammation, immunity, and vaccines for Helicobacter pylori infection. *Helicobacter* 2012; **17**: 16-21 [PMID: 22958150 DOI: 10.1111/j.1523-5378.**2012**.00977.x]

**P-Reviewers:** Carri JH, De Francesco V, Eslick GD  **S-Editor:** Cui XM

**L-Editor: E-Editor:**